Results 51 to 60 of about 21,995 (302)

Evaluation of a Novel Electric Health Record Sidecar Application to Display Rheumatoid Arthritis Clinical Outcomes During Clinic Visits: Results of a Stepped‐Wedge Cluster Randomized Pragmatic Trial

Arthritis Care &Research, EarlyView.
Objective We developed a novel electronic health record sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk, Jing Li, Cathy Nasrallah, Cherish Wilson, Alicia Hamblin, Christine Hariz, Cammie Young, Stephen Shiboski, Emma Kersey, Mary Nakamura, Judith F. Ashouri, Mehrdad Matloubian, Andrew J. Gross, Jennifer Barton, Beth Berrean, Jonathan Prugh, Jinoos Yazdany   +16 more
wiley   +1 more source

Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases

Frontiers in Immunology, 2013
Many existing therapies in autoimmune diseases are based on systemic suppression of inflammation, the observed side effects illustrate the need for more specific interventions.
Chantal eKeijzer, Ruurd eVan Der Zee, Willem eVan Eden, Femke eBroere   +3 more
doaj   +1 more source

Adjuvant formulation for veterinary vaccines: Montanide™ Gel safety profile [PDF]

, 2009
Selecting the adjuvant is one of the key for the success of the vaccine in the field. Selecting a flexible adjuvant that will fit with several vaccines dedicated to one or more animal species is a source of economical efficiency. Frequently the safety or
Parker, R., Deville, S., Dupuis, L., Bertrand, F., Aucouturier, J.   +4 more
core   +1 more source

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

Arthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J. Braaten, Gary A. Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

Improving the Effectiveness of Adjuvants: Targeting Innate Immune Receptors with a Special Focus on Toll-like Receptor Agonists

مجله دانشکده پزشکی اصفهان, 2013
The development of potent and safe adjuvants for generating vaccines capable of inducing protective and long lasting immunity has become an expanding field in vaccine development.
Seyed-Elias Tabatabaeizadeh, Alireza Haghparast   +1 more
doaj  

A model to study the impact of polymorphism driven liver-stage immune evasion by malaria parasites, to help design effective cross-reactive vaccines

Frontiers in Microbiology, 2016
Malaria parasites engage a multitude of strategies to evade the immune system of the host, including the generation of polymorphic T cell epitope sequences, termed altered peptide ligands (APLs).
Kirsty Lee Wilson, Sue Dong Xiang, Magdalena ePlebanski   +2 more
doaj   +1 more source

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

Molecular Therapy: Oncolytics, 2020
Successful in situ therapeutic vaccination would allow locally delivered oncolytic virus (OV) to exert systemic immunologic effects on metastases and improve survival.
Weilin Liu, Enyong Dai, Zuqiang Liu, Congrong Ma, Zong Sheng Guo, David L. Bartlett   +5 more
doaj   +1 more source

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling

Journal for ImmunoTherapy of Cancer, 2022
Background A goal of cancer vaccines is to induce strong T cell responses to tumor antigens, but the delivery method, schedule, and formulation of cancer vaccines have not yet been optimized.
Craig L Slingluff, Pankaj Kumar, Max O Meneveau, Kevin T Lynch, Sapna P Patel   +4 more
doaj   +1 more source

A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs [PDF]

, 1994
The adjuvanticity of a sulfolipopolysaccharide (SLP) incorporated into a squalane-in-water emulsion (SLP/S/W) was compared with that of a mineral oil-in-water (O/W) adjuvant currently used in commercial porcine vaccines.
Dazelle, T. (T.), Groenveld, B. (B.), Hilgers, L.A.Th. (L. A Th), Luitjens, A. (A.), Platenburg, P.L.I. (P. L I), Weststrate, J.T.M.   +5 more
core   +1 more source

Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]

, 2020
Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C, Lopes, A, Lopes, C, Sokolova, A   +3 more
core   +1 more source